MediPal Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

MediPal HoldingsDer Gewinn des Unternehmens wird voraussichtlich um 0.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 0.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6% betragen.

Wichtige Informationen

-0.1%

Wachstumsrate der Gewinne

0.3%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	8.7%
Wachstumsrate der Einnahmen	2.0%
Zukünftige Eigenkapitalrendite	6.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 05

Recent updates

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 05

Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes

Jun 25

Concerns Surrounding MediPal Holdings' (TSE:7459) Performance

May 22

Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E

May 08

Gewinn- und Umsatzwachstumsprognosen

TSE:7459 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	3,771,127	38,316	43,299	64,186	4
3/31/2026	3,679,761	35,624	40,990	61,622	6
3/31/2025	3,619,026	36,919	72,000	92,666	6
9/30/2024	3,604,415	46,047	56,725	72,460	N/A
6/30/2024	3,581,312	39,294	N/A	N/A	N/A
3/31/2024	3,558,732	41,474	42,448	61,843	N/A
12/31/2023	3,507,505	37,244	N/A	N/A	N/A
9/30/2023	3,453,601	38,636	40,543	56,888	N/A
6/30/2023	3,408,417	41,724	N/A	N/A	N/A
3/31/2023	3,360,008	38,806	2,642	16,146	N/A
12/31/2022	3,351,069	30,439	N/A	N/A	N/A
9/30/2022	3,333,073	28,222	11,523	26,954	N/A
6/30/2022	3,304,372	28,248	N/A	N/A	N/A
3/31/2022	3,290,921	29,423	42,339	61,216	N/A
12/31/2021	3,279,583	36,411	N/A	N/A	N/A
9/30/2021	3,265,951	30,523	25,259	45,124	N/A
6/30/2021	3,241,838	26,468	N/A	N/A	N/A
3/31/2021	3,211,125	23,926	18,780	34,448	N/A
12/31/2020	3,208,237	26,682	N/A	N/A	N/A
9/30/2020	3,186,651	33,329	58,488	84,718	N/A
6/30/2020	3,236,315	37,002	N/A	N/A	N/A
3/31/2020	3,253,079	37,968	29,565	56,917	N/A
12/31/2019	3,242,840	34,722	N/A	N/A	N/A
9/30/2019	3,253,495	35,443	15,495	33,428	N/A
6/30/2019	3,189,613	34,116	N/A	N/A	N/A
3/31/2019	3,181,928	34,359	45,225	63,716	N/A
12/31/2018	3,178,578	34,315	N/A	N/A	N/A
9/30/2018	3,169,344	34,122	55,224	75,079	N/A
6/30/2018	3,169,216	37,166	N/A	N/A	N/A
3/31/2018	3,146,314	34,780	N/A	63,558	N/A
12/31/2017	3,124,724	33,199	N/A	N/A	N/A
9/30/2017	3,093,743	31,086	N/A	45,376	N/A
6/30/2017	3,072,597	26,239	N/A	N/A	N/A
3/31/2017	3,063,900	29,011	N/A	47,954	N/A
12/31/2016	3,065,833	32,149	N/A	N/A	N/A
9/30/2016	3,072,868	32,201	N/A	53,535	N/A
6/30/2016	3,057,501	33,965	N/A	N/A	N/A
3/31/2016	3,028,187	30,771	N/A	21,985	N/A
12/31/2015	2,995,210	28,449	N/A	N/A	N/A
9/30/2015	2,953,707	26,052	N/A	25,185	N/A
6/30/2015	2,923,061	23,938	N/A	N/A	N/A
3/31/2015	2,872,905	23,687	N/A	80,466	N/A
12/31/2014	2,902,889	22,221	N/A	N/A	N/A
9/30/2014	2,909,858	21,592	N/A	55,806	N/A
6/30/2014	2,920,808	22,231	N/A	N/A	N/A
3/31/2014	2,947,798	25,485	N/A	-72	N/A
12/31/2013	2,883,615	23,157	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 7459Für die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-0.1% pro Jahr).

Ertrag vs. Markt: 7459Für die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-0.1% pro Jahr).

Hohe Wachstumserträge: 7459Für die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: 7459Die Einnahmen des Unternehmens (2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (4.2% pro Jahr).

Hohe Wachstumseinnahmen: 7459Die Einnahmen des Unternehmens (2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 7459Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6%).

MediPal Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Price target increased by 9.5% to JP¥2,475

Price target increased by 12% to JP¥2,198

Consensus EPS estimates increase by 14%

Analysts update estimates

Analysts update estimates

Recent updates

New major risk - Revenue and earnings growth

Second quarter 2025 earnings released: EPS: JP¥61.05 (vs JP¥28.08 in 2Q 2024)

Returns On Capital At MediPal Holdings (TSE:7459) Have Stalled

Upcoming dividend of JP¥30.00 per share

MediPal Holdings (TSE:7459) Will Pay A Dividend Of ¥30.00

MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024

Calculating The Fair Value Of MediPal Holdings Corporation (TSE:7459)

MediPal Holdings (TSE:7459) Has Announced A Dividend Of ¥30.00

Dividend of JP¥30.00 announced

Now 27% undervalued after recent price drop

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2025 earnings released: EPS: JP¥42.95 (vs JP¥52.32 in 1Q 2024)

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes

MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024

MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).

Concerns Surrounding MediPal Holdings' (TSE:7459) Performance

Full year 2024 earnings: EPS exceeds analyst expectations

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.

Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E

MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023)

MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023)

Price target increased by 9.5% to JP¥2,475

Upcoming dividend of JP¥30.00 per share at 2.3% yield

MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023)

Price target increased by 12% to JP¥2,198

MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 14%

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥23.00 per share at 2.6% yield

Now 22% undervalued

Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022)

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Upcoming dividend of JP¥23.00 per share

MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022)

MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Upcoming dividend of JP¥21.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 20% undervalued

Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021)

Upcoming dividend of JP¥21.00 per share

First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020)

Upcoming dividend of JP¥21.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021

Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020)

Revenue and earnings beat expectations

New 90-day high: JP¥2,141

Analysts update estimates

Analysts update estimates

MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021

MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020